Key result
Vascular disrupting agents fail to improve survival and are hampered by significant toxicities.
Why the study?
Do vascular disrupting agents improve survival in patients with solid tumors?
Do vascular disrupting agents improve survival in patients with solid tumors?
Vascular disrupting agents have failed to show a survival advantage in solid tumors and are limited by significant cardiovascular, neurological, and hematological toxicities.
No takes yet. Share an insight, caveat, or question.
Vascular disrupting agents should not enter clinical use for solid tumors; leaves open whether refined agents or combinations can surmount prior efficacy and toxicity barriers.
Hollebecque et al. (2012) conducted a review in Cancer. Vascular disrupting agents was evaluated. Vascular disrupting agents have failed to demonstrate a survival advantage in several phase II/III trials, and their clinical development is hampered by significant toxicities.
Synapse has enriched one closely related paper. Consider it for comparative context: